{
    "ticker": "CVM",
    "name": "Celldex Therapeutics, Inc.",
    "description": "Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for cancer and other serious diseases. Founded in 2004 and headquartered in Hampton, New Jersey, Celldex aims to leverage its proprietary technologies to create innovative therapies that address unmet medical needs. The company is particularly recognized for its work in immuno-oncology, where it develops products that harness the body\u2019s immune system to fight cancer. Celldex's lead product candidate, the monoclonal antibody CDX-011, is designed for treating various forms of cancer, specifically those expressing the GPNMB protein. The company is also working on a range of other candidates, including vaccines and antibody-drug conjugates, to target different types of tumors. Celldex is committed to advancing its pipeline through rigorous clinical trials, collaborating with research institutions, and engaging with regulatory agencies. With a focus on innovation and patient-centric approaches, Celldex is positioned to make significant contributions to the field of oncology and improve outcomes for patients globally.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Hampton, New Jersey, USA",
    "founded": "2004",
    "website": "https://www.celldextherapeutics.com",
    "ceo": "Anthony Marucci",
    "social_media": {
        "twitter": "https://twitter.com/Celldex",
        "linkedin": "https://www.linkedin.com/company/celldex-therapeutics/"
    },
    "investor_relations": "https://investors.celldextherapeutics.com",
    "key_executives": [
        {
            "name": "Anthony Marucci",
            "position": "CEO"
        },
        {
            "name": "Scott P. J. H. S. R. C. C. D. N. F",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "CDX-011",
                "CDX-1401"
            ]
        }
    ],
    "seo": {
        "meta_title": "Celldex Therapeutics, Inc. | Innovating Cancer Treatments",
        "meta_description": "Learn about Celldex Therapeutics, Inc., a leader in developing targeted cancer therapies. Explore their innovative product pipeline and commitment to oncology.",
        "keywords": [
            "Celldex",
            "Biotechnology",
            "Cancer Treatments",
            "Immuno-oncology",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Celldex Therapeutics focus on?",
            "answer": "Celldex Therapeutics focuses on developing targeted therapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Celldex Therapeutics?",
            "answer": "Anthony Marucci is the CEO of Celldex Therapeutics, Inc."
        },
        {
            "question": "Where is Celldex headquartered?",
            "answer": "Celldex is headquartered in Hampton, New Jersey, USA."
        },
        {
            "question": "What are Celldex's main product candidates?",
            "answer": "Celldex's main product candidates include CDX-011 and CDX-1401."
        },
        {
            "question": "When was Celldex founded?",
            "answer": "Celldex was founded in 2004."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "REGN",
        "MRNA"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "GILD",
        "VRTX"
    ]
}